Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 3/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | IL1RN | P18510 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | STK16 | O75716 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17404463 | 0.93 | ACLY (0.53) | ACLYKEAP1CA1CA2GBA1 | |
| SCHEMBL22619046 | 0.80 | GAK (0.44) | ACLYCA1CA2GAKSTK16 | |
| SCHEMBL10443735 | 0.77 | CA2 (0.54) | KEAP1CA1CA2IL1RNERAP1 | |
| SCHEMBL22928007 | 0.76 | EPHA3 (0.43) | CA1CA2CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL12678587 | 0.75 | HDAC1 (0.37) | ACLYALDH1A1GAKSTK16AAK1 | |
| SCHEMBL15672897 | 0.74 | CA2 (0.56) | KEAP1CA1CA2IL1RNERAP1 | |
| SCHEMBL6533144 | 0.74 | CA1 (0.56) | KEAP1CA1CA2IL1RNERAP1 | |
| SCHEMBL22619016 | 0.74 | ACLY (0.44) | ACLYCA1CA2GAKSTK16 | |
| SCHEMBL19808493 | 0.74 | KEAP1 (0.39) | KEAP1CA1CA2IL1RNERAP1 | |
| SCHEMBL97856 | 0.74 | ACLY (0.41) | ACLYKMT2AMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | CORNELL UNIVERSITY | 2021-08-19 | — | — | US | disclosed |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10800750-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10472342-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10457655-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10450286-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-10399951-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190241533-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| US-20190241532-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2018-02-22 | — | — | US | disclosed |
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2018-02-22 | — | — | US | disclosed |
| US-20170312273-A1 | METHODS OF USING FASN INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170312273-A1 | METHODS OF USING FASN INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20160002188-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2016-01-07 | — | — | US | disclosed |
| US-20160002188-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241533-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | ACLY 537/4885KEAP1 753/4885CA1 3455/4885 |
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | ACLY 537/4885KEAP1 753/4885CA1 3455/4885 |
| US-10399951-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | ACLY 496/4885KEAP1 913/4885CA1 2541/4885 |
| US-20170312273-A1 | METHODS OF USING FASN INHIBITORS | FASN, IL1RN, CCR1 | ACLY 2800/4885KEAP1 1395/4885CA1 797/4885 |
| US-10472342-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | ACLY 393/4885KEAP1 868/4885CA1 2375/4885 |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | AIFM2, FABP7, FASN | ACLY 2348/4885KEAP1 3382/4885CA1 2462/4885 |
| US-10450286-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | ACLY 393/4885KEAP1 868/4885CA1 2375/4885 |
| US-20160002188-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | ACLY 537/4885KEAP1 753/4885CA1 3455/4885 |
| US-20190241532-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | ACLY 537/4885KEAP1 753/4885CA1 3455/4885 |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | ACLY 537/4885KEAP1 753/4885CA1 3455/4885 |
| US-10457655-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | ACLY 393/4885KEAP1 868/4885CA1 2375/4885 |
| US-10800750-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | ACLY 393/4885KEAP1 868/4885CA1 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.